These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 21982327

  • 1. Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
    Augoustides JG.
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):1208-12. PubMed ID: 21982327
    [Abstract] [Full Text] [Related]

  • 2. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C, Barrios V, Jimenez D.
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [Abstract] [Full Text] [Related]

  • 3. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D, Hull R, Fareed J.
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [Abstract] [Full Text] [Related]

  • 4. Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
    Alonso-Coello P, Zhou Q, Guyatt G.
    Thromb Haemost; 2012 Oct; 108(4):647-53. PubMed ID: 22918481
    [Abstract] [Full Text] [Related]

  • 5. Place of dabigatran in contemporary pharmacotherapy.
    Gums JG.
    Pharmacotherapy; 2011 Apr; 31(4):335-7. PubMed ID: 21449622
    [No Abstract] [Full Text] [Related]

  • 6. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [Abstract] [Full Text] [Related]

  • 7. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE, Spinler SA.
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [Abstract] [Full Text] [Related]

  • 8. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
    Bendel SD, Bona R, Baker WL.
    Adv Ther; 2011 Jun; 28(6):460-72. PubMed ID: 21533567
    [Abstract] [Full Text] [Related]

  • 9. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
    Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.
    J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
    [Abstract] [Full Text] [Related]

  • 10. [Dabigatran, a new oral anticoagulant].
    Uchiyama S.
    Brain Nerve; 2011 Apr; 63(4):411-5. PubMed ID: 21441645
    [Abstract] [Full Text] [Related]

  • 11. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.
    Garwood CL, Hwang JM, Moser LR.
    Pharmacotherapy; 2011 Dec; 31(12):1208-20. PubMed ID: 22122182
    [Abstract] [Full Text] [Related]

  • 12. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV, Quinlan DJ, Dahl OE, Schulman S.
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [Abstract] [Full Text] [Related]

  • 13. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
    Fieland D, Taylor M.
    Ann Pharmacother; 2012 Jan; 46(1):e3. PubMed ID: 22202498
    [Abstract] [Full Text] [Related]

  • 14. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M, CCS Atrial Fibrillation Guidelines Committee.
    Can J Cardiol; 2011 Jan; 27(1):74-90. PubMed ID: 21329865
    [Abstract] [Full Text] [Related]

  • 15. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
    [Abstract] [Full Text] [Related]

  • 16. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B, Faille D, Ajzenberg N.
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [Abstract] [Full Text] [Related]

  • 17. Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
    Brem E, Koyfman A, Foran M.
    J Emerg Med; 2013 Jul; 45(1):143-9. PubMed ID: 23375217
    [Abstract] [Full Text] [Related]

  • 18. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
    Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, van Ryn J, Lehr T.
    Curr Med Res Opin; 2012 Feb; 28(2):195-201. PubMed ID: 22208675
    [Abstract] [Full Text] [Related]

  • 19. [Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
    Calvo Romero JM.
    Rev Clin Esp; 2011 Mar; 211(3):142-6. PubMed ID: 21371701
    [Abstract] [Full Text] [Related]

  • 20. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
    Blommel ML, Blommel AL.
    Am J Health Syst Pharm; 2011 Aug 15; 68(16):1506-19. PubMed ID: 21817082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.